Conference Proceedings

Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion non-small cell lung cancer (NSCLC).

Benjamin Besse, Alexander E Drilon, Benjamin J Solomon, Vivek Subbiah, Daniel Shao-Weng Tan, Keunchil Park, Filippo G De Braud, Guzman Alonso, Juergen Wolf, Victoria Soldatenkova, Aimee K Lin, Pearl Plernjit French, Koichi Goto, Oliver Gautschi

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2021


9065 Background: Selpercatinib, a first-in-class highly selective and potent, CNS-active RET kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ lung or thyroid cancers. Here we report an update of efficacy and safety results which provide a longer follow up and increased number of patients (safety population: N = 345 vs N = 329). Methods: Pts with RET fusion+ NSCLC enrolled in the global, multicenter, ongoing LIBRETTO-001 trial (NCT03157128; 16 countries, 89 sites) were included in this analysis. Pts with the opportunity to be followed ≥6 months from their first dose were included in the efficacy-evaluable population for these analyses. Integrated analysis set ..

View full abstract


Citation metrics